Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection

Liver International

Volumn 31, Issue 3, 2011, Pages 340-347

  Watanabe, Masaaki ^a   Shibuya, Akitaka ^a   Tsunoda, Yuhko ^a   Danbara, Mikio ^a   Ishii, Ryuji ^a   Ohsaka, Manabu ^a   Takada, Juichi ^a   Tanaka, Yoshiaki ^a   Okuwaki, Yusuke ^a   Minamino, Tsutomu ^a   Hidaka, Hisashi ^a   Nakazawa, Takahide ^a   Horie, Ryouichi ^a   Higashihara, Masaaki ^a   Koizumi, Wasaburo ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; de novo HBV related hepatitis; Entecavir; HBV reactivation; Rituximab

Indexed keywords

ACLARUBICIN; CARBOPLATIN; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ENTECAVIR; ETOPOSIDE; IDARUBICIN; IMATINIB; IRINOTECAN; MELPHALAN; MITOXANTRONE; PIRARUBICIN; RETINOIC ACID; RITUXIMAB; SOBUZOXANE; VINCRISTINE SULFATE; VIRUS DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DNA DETERMINATION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAPANESE; LYMPHOMA; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; VIRUS REACTIVATION; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 79551506218     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02417.x     Document Type: Article

References (20)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
3. Tanaka J, Kumagai J, Katayama K, et al. Sex-and age-specific carriers of hepatitis B and C Viruses in Japan estimated by the prevalence in the 3485648 first-time blood donors during 1995-2000. Intervirology 2004; 47: 32-40.
4. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
6. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712.
7. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007; 37: 705-12.
8. Tanaka E, Umemura T. History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world. Clin J Gastroenterol 2008; 1: 83-6.
9. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-65.
10. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-8.
11. Nancy WY, John ST, Gene TC, et al. Hepatitis B virus DNA in peripheral blood leukocytes. Cancer 1994; 73: 1143-8.
12. Umeda M, Marusawa H, Seno H, et al. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J Hepatol 2005; 42: 806-12.
13. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
14. Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008; 47: e52-6.
15. Marie A, Afonso R. Prevention of HBV reactivation from anti-HBc-positive liver grafts: searching for the consensus. J Hepatol 2004; 40: 186-8.
16. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23.
17. Hui CK, Lie A, Au WY, et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005; 106: 464-9.
18. Olioso D, Boaretti M, Ligozzi M, Lo Cascio G, Fontana R. Detection and quantification of hepatitis B virus DNA by SYBR green real-time polymerase chain reaction. Eur J Clin Microbiol Infect Dis 2007; 26: 43-50.
19. Mizokami M, Nakano T, Orito E, et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999; 450: 66-71.
20. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.